Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Temozolomide (Temodar).

Literature DB >> 20538821

Temozolomide (Temodar).

J R Wesolowski¹, P Rajdev, S K Mukherji.

Abstract

Temozolomide, an oral alkylating agent, is a commonly used medicine in the treatment of anaplastic astrocytoma and glioblastoma multiforme. This paper will present the mechanism of action as well as the clinical role for this chemotherapeutic drug.

Entities: Chemical Disease

Mesh：

Substances：

Year: 2010 PMID： 20538821 PMCID： PMC7966084 DOI： 10.3174/ajnr.A2170

Source DB: PubMed Journal: AJNR Am J Neuroradiol ISSN： 0195-6108 Impact factor: 3.825

8 in total

Review 1. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials.

Authors: E S Newlands; M F Stevens; S R Wedge; R T Wheelhouse; C Brock
Journal: Cancer Treat Rev Date: 1997-01 Impact factor: 12.111

Review 2. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.

Authors: S S Agarwala; J M Kirkwood
Journal: Oncologist Date: 2000

Review 3. Temozolomide and treatment of malignant glioma.

Authors: H S Friedman; T Kerby; H Calvert
Journal: Clin Cancer Res Date: 2000-07 Impact factor: 12.531

Review 4. Temozolomide for the treatment of metastatic melanoma: a systematic review.

Authors: Ian Quirt; Shailendra Verma; Teresa Petrella; Kate Bak; Manya Charette
Journal: Oncologist Date: 2007-09

Review 5. Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature.

Authors: Nimit Singhal; Sudarshan Selva-Nayagam; Michael P Brown
Journal: J Neurooncol Date: 2007-05-26 Impact factor: 4.130

Review 6. The economics of temozolomide in brain cancer.

Authors: Ralph Crott
Journal: Expert Opin Pharmacother Date: 2007-08 Impact factor: 3.889

Review 7. Temozolomide in malignant gliomas: current use and future targets.

Authors: J Lee Villano; Tara E Seery; Linda R Bressler
Journal: Cancer Chemother Pharmacol Date: 2009-06-19 Impact factor: 3.333

Review 8. Temozolomide: realizing the promise and potential.

Authors: R Nagasubramanian; M Eileen Dolan
Journal: Curr Opin Oncol Date: 2003-11 Impact factor: 3.645

8 in total

19 in total

Review 1. Using the molecular classification of glioblastoma to inform personalized treatment.

Authors: Adriana Olar; Kenneth D Aldape
Journal: J Pathol Date: 2014-01 Impact factor: 7.996

2. Current clinical management of patients with glioblastoma.

Authors: Stephen Lowe; Krishna P Bhat; Adriana Olar
Journal: Cancer Rep (Hoboken) Date: 2019-09-04

3. Investigating the Stability of Six Phenolic TMZ Ester Analogues, Incubated in the Presence of Porcine Liver Esterase and Monitored by HPLC.

Authors: Leroy A Shervington; Oliver Ingham
Journal: Molecules Date: 2022-05-05 Impact factor: 4.927

Review 4. Neuro-oncologic Emergencies.

Authors: Paola Suarez-Meade; Lina Marenco-Hillembrand; Wendy J Sherman
Journal: Curr Oncol Rep Date: 2022-03-30 Impact factor: 5.945

10. Standardized orthotopic xenografts in zebrafish reveal glioma cell-line-specific characteristics and tumor cell heterogeneity.

Authors: Alessandra M Welker; Brian D Jaros; Vinay K Puduvalli; Jaime Imitola; Balveen Kaur; Christine E Beattie
Journal: Dis Model Mech Date: 2015-12-10 Impact factor: 5.758